Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin - One-year observational study

• Published in: National journal of physiology, pharmacy and pharmacology Vol. 11; no. 1; pp. 1 - 108
• Main Authors: Chandran, Anu, Mathai, Paul, Raveendran, Laveesh, Raghavan, Varun, S, Premlal
• Format: Journal Article
• Language: English
• Published: Surat Association of Physiologists, Pharmacists & Pharmacologists 01.01.2021
• Subjects: Cancer therapies; Chemotherapy; Developing countries; Drug dosages; Hydration; Industrialized nations; Laboratories; LDCs; Lung cancer; Observational studies; Patients; Population; Tumors; India
• ISSN: 2320-4672; 2231-3206
• DOI: 10.5455/njppp.2021.11.11308202002412020

Aim and Objective: The primary objective was to study and grade the various toxicities of paclitaxel (PTX) - cisplatin (CDDP) combination, using the World Health Organization's toxicity grading scale. Cancer Treatment; Drug Toxicity Profile; Lung Cancer; National Securities Clearing Corporation Ltd.; Paclitaxel-Cisplatin Regimen, Stage II Non-small Cell Lung Cancer; The World Health Organizations Toxicity Criteria INTRODUCTION With 7.6 million deaths annually, cancer is the leading cause of death in developed countries and the second leading cause in developing countries.14 The burden of cancer increases in developing countries as a result of demographic transition and changes in lifestyle associated with known risk factors of cancer, including overconsumption of faulty diets (junk food), being physically inactive, and tobacco use. [...]the current research aims to study and grade the toxicities of this regimen for NSCLC in the Indian population using locally followed protocols. According to the WHO toxicity grading scale, the toxicities developed by the patients in this study setting, are graded.